ESR1 and breast carcinoma: Similar result was observed in breast cancer, where it was possible to stratify a patient cohort based on regulon activity [13].In the same work, the authors have shown that the pharmacological inhibition of estrogen receptor drastically suppresses the ESR1 regulon.